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The safety and efficacy of a medicine must be evaluated through appro­
priate studies before it can be registered and made commercially avail­
able. [1] In South Africa (SA), the Medicines Control Council (MCC) 
is mandated to oversee the registration of new medicines.[2] In order 
to be registered, before permission to sell is granted, medicines must 
demonstrate acceptable levels of safety, quality and efficacy.[3] These 
requirements are achieved by clinical trials carried out by the applicant. 
In SA, all clinical trials must be authorised, which means that 
they must be registered in the South African National Clinical Trials 
Register (SANCTR) before commencement.[3] In most clinical trials, 
safety and efficacy are demonstrated by comparing several predefined 
outcomes in a treatment group and a control group. The control 
group is either treated with the standard treatment or a placebo.[4] 
The comparison of the outcomes from the treatment group and the 
control group should show whether the new treatment is efficacious 
and safe and whether it can be adopted as the new standard in the 
treatment of the disease in question.[5]
In a medical environment that supports evidence­based medicine, 
clinicians and patients base their choice of medicines on published 
clinical trial results.[1] Ideally, all the clinical information that leads to 
a medicine’s approval should be publicly available to help clinicians 
make informed decisions about how to treat their patients.[6] 
A full­length peer­reviewed article in a medical journal is the 
primary method by which clinical trial results are communicated to 
the scientific community and the general public.[6] An incomplete 
view of the safety and efficacy of the medicine compared with 
other treatments is created when the results of clinical trials are not 
published, which may cause prescribing bias by clinicians towards 
this new treatment.[7] Furthermore, publication of the clinical trial 
outcome establishes that the research was done in a scientifically 
transparent and ethical manner. Peer review adds credibility to the 
findings of the research. Without publication, claims of a medicine’s 
efficacy and safety are only hearsay.[6]
The SA guidelines for clinical trials prescribe the following 
procedure in the publication of trial results. [3]
 ‘Sponsors and investigators have an ethical obligation to disseminate 
research results, whether positive or negative, in a timely manner. It 
is however important that the release of research findings be done in 
an ethical manner, to ensure that false expectations are not raised in 
a vulnerable population. Research results should not be prematurely 
released or published, or unreasonably delayed. It is advisable 
that the main results should be disseminated, using appropriate 
communication formats, to the participants and other interested 
members of the communities in which the study was conducted.’
 
Despite the above guidelines, the results of some clinical trials remain 
unpublished and this can contribute to publication bias, a type of reporting 
in which the results of completed studies are left unpublished. [8] Sometimes, 
the decision whether or not to publish the results of clinical trials may 
depend on the nature and direction of the research findings. Internationally, 
trials with positive outcome measures are more often published than those 
with negative outcomes. [6] This occurs because it is more favourable for 
pharmaceutical companies, in their marketing efforts, to utilise data in which 
their medicine performs well. Clinical trial results in which the medicine 
performs badly against the standard of treatment, or in which there is no 
clinically significant advantage, are seldom published.[6]
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Publication bias may also occur for other reasons, including editors 
of scientific journals rejecting research findings that have non­
significant or negative findings or academics simply not completing 
the process of publishing their results.[8] Another type of reporting 
bias is the time­lag bias where the publication of research findings is 
delayed depending on the nature of the results.[8]
Some well­documented reports concerning the concealment and 
delayed release of outcome data of the medicine rofecoxib (Vioxx; 
Merck, USA) in the USA raised awareness of the limited and 
incomplete public access to clinical trial results for FDA­approved 
medicines. Merck, the manufacturer of rofecoxib, acted unethically 
by withholding information about rofecoxib’s safety from doctors and 
patients for >5 years, resulting in between 88 000 and 140 000 cases 
of serious heart disease.[7] This case resulted in a determined effort to 
achieve improved disclosure of trial results.[7] 
The antidiabetic medicine rosiglitazone (Avandia; GlaxoSmith­
Kline, UK) is another example where safety data obtained during 
clinical trials were concealed. Post­marketing surveillance showed an 
increased risk of cardiac events with the use of this medicine, which 
eventually resulted in its withdrawal from the market after 11 years 
of use.[9]
Oseltamivir (Tamiflu; Roche, Switzerland) has been marketed 
by Roche since 1999 as an antiviral medication for the treatment of 
influenza virus types A and B. Based on the evidence available at 
the time, it was included in the World Health Organization (WHO) 
essential medicines list in 2011.[10] Prior to the global outbreak of H1N1 
influenza in 2009, the USA alone had stockpiled nearly USD1.3 billion 
worth of the antiviral.[10] In 2012, the Cochrane Collaboration was 
finally granted access to evidence which had previously been concealed 
and had remained unpublished. This evidence did not support the 
claims that oseltamivir lowered the risk of complications from influenza 
and that it decreased viral transmission or that the benefits of using 
this medicine outweighed the risks.[10] Globally, over USD17 billion of 
public money was spent on stockpiling a medicine of uncertain benefit, 
as a result of decisions based on incomplete data.[10]
A study conducted in the USA on 909 clinical trials in the period 
1998 to 2000 showed that over half (57%) of all trials in the USA 
for FDA­approved medicines remained unpublished >5 years after 
approval. The majority (364/394; 92.4%) of the trials that were 
published were published within 3 years of FDA approval. The 
study also reported that trials with statistically significant positive 
results and larger sample sizes were more likely to be published. 
Furthermore, it was evident that selective reporting of trial results 
exists for commonly marketed drugs.[11]
The US Food and Drug Agency (FDA) through the Food and 
Drug Administration Amendments Act of 2007 (FDAAA) made it 
mandatory for the results of all clinical trials to be published within a 
year of completion. An audit done in 2012 showed that close to 80% 
of trials failed to comply with the requirement to publish clinical trial 
results within 1 year of completion. Notwithstanding this situation, 
no fines have yet been issued for non­compliance.[12] 
To address the situation of incomplete outcomes data, the AllTrials 
campaign was initiated by some clinicians in Europe. The AllTrials 
campaign advocates for the principles of open research including 
improved transparency of clinical trials outcomes. The campaign 
summarises its objectives using the mantra ‘All trials registered, all 
results reported’, meaning that all clinical trials should be listed in 
a clinical trials registry, and their results should always be shared as 
open data. It argues that ‘Evidence Based Medicine would be so much 
better if we had ALL the evidence.’[13] 
In SA, there is no legal requirement to compel principal investi­
gators and/or their sponsors to publish the results of clinical trials, 
although they have an ethical obligation to do so. This article 
describes an attempt to determine the level of clinical trials reporting 
and publication in SA.
Objectives
To determine the publication rate and average time to reporting 
for clinical trials carried out in SA and to explore the factors that 
determine whether a study is published or not.
Methods
Study design
The study was a registry­based quantitative retrospective analysis of 
SA clinical trials for new medicinal products approved and registered 
between January 2008 and December 2010.
Sample selection
The SANCTR is the legally mandated register for clinical trials in 
SA.[3] However, it does not meet the criteria for a primary register set 
out by the WHO or the International Committee of Medical Journal 
Editors (ICMJE).[14] As such, SA clinical trial investigators who plan 
to meet WHO requirements for transparency and publication need 
to register with both SANCTR and a WHO­ or ICJME­recognised 
register such as the USA ClinicalTrials.gov register. A limitation of 
the SANCTR is that it often has incomplete trial information on 
the register for essential data sets. The ClinicalTrials.gov register 
is a more information­rich database and has data sets such as trial 
identification number, trial completion date, primary and secondary 
outcome measures and funding source. The ClinicalTrials.gov 
website was deemed to be a more useful registry for the purposes of 
this study and incidentally recorded more SA clinical trials than the 
SANCTR in the study period (a subset of 1 190 SA trials registered on 
the ClinicalTrials.gov website v. 665 on the SANCTR website). These 
1 190 clinical trials investigating new medicines classified as ‘new 
molecular entities’ (medicinal products that have not previously been 
approved by the MCC for any indication) for safety and/or efficacy 
were registered in the period January 2008 ­ December 2010. 
From the subset of 1 190 trials and with an alpha error level 
of 0.1, beta 0.5, a minimum sample size of 65 was required with 
~10% precision level.[15] A sample of 79 clinical trials was then 
randomly selected for this study from the 1 190 trials registered on 
the ClinicalTrials.gov website using the random number generation 
method on Microsoft Excel (USA). 
Determination of publications in journals and  
search strategy
For each of the selected 79 clinical trials, the unique international 
trial identification number as listed on the registry was used to track 
all subsequent publications. Tracking of clinical trials was done 
through a systematic literature search of electronic journal databases 
of the South African Medical Journal (SAMJ), the Cochrane Library, 
Public Library of Science Medical Journal (PLoS Medicine), and 
BioMed Central, all of which are indexed in MEDLINE via PubMed. 
In addition, a manual search of the Open Access Journal of Clinical 
Trials databases and reference lists on articles related to the trial 
medicine was performed. Non­peer­reviewed journals were excluded 
from the search as the process to ascertain the quality of articles 
included in such journals was deemed too time­consuming for the 
purposes of this study and because such articles are not regarded as 
reliable evidence and are sometimes ‘advertorial’ in nature.
The tracking of possible publications in the electronic journals was 
done for the period starting from the registration of each clinical trial 
as recorded in the register until the date of the data collection.
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Clarification of covariates 
The variables for every clinical trial tracked were defined and 
recorded as follows: Whether or not the clinical trial was 
completed (Yes/No) as stated in the registry and the date of 
completion of the clinical trial if available. Dates of registration 
and commencement of the clinical trials were also recorded if 
available (1st day of the month if only month and year were 
recorded in the register). The funding source was categorised as 
‘funded by industry’ or ‘funded by academia’ or ‘other’. The study 
phases (either clinical trial phase I, II, III or IV) were recorded as 
stated on the register. For the purposes of this study, if the study 
was considered by the principal investigator to cover more than 
one phase, the highest phase was recorded. 
The study designs were characterised as either ‘randomised, 
double­blind with standard care as comparator’ or ‘randomised, 
double­blind, placebo­controlled trial’ or ‘not clear’. Therapeutic 
areas of the clinical trial were categorised as HIV and AIDS, 
respiratory disease, cardiovascular disease, diabetes, childhood 
diseases (vaccines), reproductive system, central nervous system 
and other. Location of the study was categorised as ‘South 
Africa only’ or a multinational study. Because interventional 
studies were only considered in this study, the primary outcome 
measure of each clinical trial was categorised as ‘safety’, ‘efficacy’ 
or ‘both safety and efficacy’. A completed study was considered 
published if the results of the primary outcome were published 
in a peer­reviewed journal. The earliest publication date was 
used in the case of multiple publications. Other possible 
covariates such as subject ages and number of subjects were 
excluded from the study.
Ethical considerations
Ethical clearance for the study was obtained from the Sefako 
Makgatho Health Sciences University Research Ethics Committee 
(MREC/H/228/2014 as amended) before commencement of the data 
collection.
Data analysis
The ClinicalTrials.gov registry stated whether the trial was 
completed or not and also stated the trial completion date where 
applicable. The time to publication (TTP) was calculated by 
subtracting the trial completion date from the publication date. 
The mean and standard deviation (SD) were calculated for the 
TTP. Frequencies and proportions (%) were calculated to describe 
categorical variables such as funding source, study phases, study 
design, therapeutic areas, location of the study and primary 
outcome measure.
Results
Characteristics of clinical trials
Table 1 shows summary characteristics for the clinical trials sur veyed. 
The majority (n=72; 91.1%) of the 79 trials surveyed were completed. 
Seventy studies (88.6%) were funded solely by the industry while only 
2.5% were funded by academia. The majority of the clinical trials 
(60.8%) were phase III studies, followed by phase II trials (26.6%), 
phase IV (8.9%) and lastly phase I clinical trials (3.8%). 
Forty­three (54.4%) clinical trials were randomised and double­
blinded, with standard care as the comparator, against 32 (40.5%) 
randomised, double­blinded, placebo­controlled trials. All studies 
surveyed were located in SA (as per inclusion criteria), with 81.0% 
of them being multicentre studies with study locations in other 
countries as well. The major primary outcome measure was efficacy 
(60.8%), followed by safety (17.7%).
Publication of clinical trial results 
The publication profiles of SA clinical trials are presented in Table 2.
Of the 72 trials concluded only 35 (48.6%) had the results published 
in a peer­reviewed journal. Twenty­nine (82.9%) of the trials that 
were published had a positive outcome. Of the subset of 35 trials that 
were published, 77.1% were published within 2 years. The mean TTP 
was 21.8 months (SD 17.7).
Table 1. Characteristics of clinical trials (CTs) surveyed (N=79)
Characteristics n (%)





Study phase (higher phase if more than one phase)
Phase I 3 (3.8)
Phase II 21 (26.6)
Phase III 48 (60.8)
Phase IV 7 (8.9)
Type of study
 Randomised, double­blind with standard care as 
comparator
43 (54.4)
Randomised, double­blind, placebo­controlled trial 32 (40.5)
Not clear 4 (5.1)
Therapeutic area of study
Respiratory disease 14 (17.7)
HIV and AIDS 11 (13.9)
Cardiovascular 11 (13.9)
Diabetes 11 (13.9)
Central nervous system 10 (12.7)
Reproductive system 7 (8.9)
Childhood diseases (vaccines) 1 (1.3)
Other 14 (17.7)
Location of study
Multinational study (including SA) 64 (81.0)
SA only 15 (19.0)
Primary outcome measure achieved
Efficacy 48 (60.8)
Both safety and efficacy 17 (21.5)
Safety 14 (17.7)
Table 2. Publication of SA CTs
CT characteristic N n (%)
CT registered 79 79 (100)
CT completed 79 72 (91.1)
CT completed with results published 72 35 (48.6)
CT published with a positive outcome 35 29 (82.9)
CT published within 2 years 35 27 (77.1)
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Discussion
Most trials in the sample covered by this 
investigation were completed. However, 
more than half (52%) of the clinical trials 
surveyed failed to achieve transparency 
and did not release their findings into the 
public domain. The results are comparable 
with a study published in the USA in 2008 
which reported that over half (57%) of 
909 trials in the USA for FDA­approved 
medicines between 1998 and 2000 remained 
unpublished >5 years after approval.[11] 
Another study carried out in the USA in 
2014 after the introduction of the FDAAA 
in 2007 indicated an improvement in publi­
cation rates, with 118 out of 400 (29.5%) 
clinical trials failing to disseminate their 
results within 4 years of completion.[16] An 
audit done in 2012 showed that 78% of 
trials failed to comply with the updated 
requirement to publish results within 1 
year. [12] In Fin land, a study done in 1998 on 
188 clinical trials by the Finnish National 
Agency for Medicines showed that selective 
reporting was prevalent, with a reporting 
rate of 30.3% (57/188) on clinical trials 
surveyed.[17] 
Table 3 shows a comparison of the USA 
(2008 and 2014) and Finland (1998) country 
studies with this SA study. SA clinical trials 
carried out in the period 2008 to 2010 had 
a similar publication rate in 2014 to that for 
clinical trials carried out in the USA in the 
period 1998 to 2000 and a slightly better 
publication rate than the Finnish study 
carried out in 1998. This situation occurred 
despite increased awareness and advocacy 
for all clinical trials to be published.[13] 
This study suggests that the results of 
the clinical trial had a bearing on whether 
the study would be published or not. 
Twenty­nine (83%) clinical trials with 
positive findings for the primary outcome 
were published. The 1998 Finnish study 
also demonstrated a similar trend; trials 
with positive outcomes (76%) were reported 
more often than those with inconclusive 
or negative outcomes.[17] The current study 
shows that 71% of the clinical trials were 
published within 2 years of completion. The 
2008 USA study revealed that a majority 
(92%) of the trials published were published 
within 3 years of FDA approval.[11] 
The frequency of placebo­controlled 
trials (40.5%) requires further interrogation. 
The Declaration of Helsinki states that trial 
participants ‘should be assured of the best 
proven diagnostic and therapeutic method’ 
and that no patient should be denied the 
‘standard of care’.[18]
Respiratory diseases, HIV and AIDS, 
cardio vascular diseases and diabetes were 
the most surveyed illnesses in the clinical 
trials surveyed with frequencies of 17.7%, 
13.9%, 13.9% and 13.9%, respectively. Des­
pite the relatively small sample size and the 
associated biases, this profile almost matches 
local disease trends,[19] and could indicate 
that the clinical trials carried out here are, 
in actual fact, relevant to SA’s disease profile.
Study limitations
Our study had two main limitations. Firstly, 
the study was a registry­based analysis of 
the Clinicaltrials.gov website. The study 
depended largely on the reliability of the 
data in this online repository and assumed 
that the data were complete and accurate. 
Secondly, similar studies point to an average 
TTP of 27 months. A decision was therefore 
taken to offer a 4­year grace period from trial 
completion to determine TTP. This resulted 
in the study being limited to clinical trials 
completed by December 2010. It excluded 
trials completed in subsequent years. It 
is possible, as shown in the USA studies 
published in 2008[11] and 2014,[16] that there 
could be improved publication rates for SA 
clinical trials completed after 2010. This 
matter needs to be investigated further and 
may form the basis of continued study on 
this topic. Nevertheless, this study did take 
into consideration publication of results that 
occurred until December 2014. 
As suggested by Saito and Gill,[16] other 
risk factors such as funding mechanism, age 
of participants in clinical trials or sample 
size could influence publication behaviour 
of researchers, which warrants further 
investi gation for trials carried out in SA. 
An interrogation of principal investigators 
and sponsors of clinical trials that were not 
published also needs to be carried out to 
establish the reasons why the investigators 
had not published the trial results.
Conclusion
This study determined the peer­reviewed 
publication rate and TTP for clinical trials 
carried out in SA, as well as other factors 
which affect these variables. The absence of 
complete outcomes data from clinical trials 
is scientific misconduct and has the effect of 
providing an incomplete view of the safety 
and efficacy of the medicine tested compared 
with other treatments. This situation may 
cause prescribing bias by clinicians as a 
result of overestimation of the benefits of 
the new treatment and underestimation of 
the harmful effects, thereby putting patients 
at risk.
The study puts forward a case to the regu­
latory body, medical professional bodies and 
research ethics committees to compel all 
data from clinical trials to be made accessible 
to clinicians and the general public by being 
published in a peer­reviewed journal or 
in any other easily accessible form, e.g. 
an open register, as mooted by AllTrials.
com. National central repositories within 
countries, such as the SANCTR, would also 
be a helpful platform for posting clinical trial 
results. A model which the SA regulatory 
agency could emulate is the International 
Standard Randomised Controlled Trial 
Number (ISRCTN) of BioMed Central. The 
ISRCTN is an official primary registry of 
the WHO registry network. It contains the 
basic set of data items for clinical trials 
registration prescribed by the WHO and 
the ICMJE guidelines. Furthermore, the 
FDAAA requires compulsory registration 
of summaries of trial results for clinical 
trials with ClinicalTrials.gov by responsible 
parties, within 1 year of completion of the 
trial.[20] A similar initiative of including a 
summary of the results for each clinical 
trial as an additional data set in the 
register could be worth consideration by 
the SANCTR.
Table 3. Comparison of CT reporting studies: SA, USA[11,16] and Finland[17] 
CT characteristic SA USA (n=909) USA (n=400) Finland (n=188)
Year of publication Current study 2008 2014 1998
Period under study 2008 ­ 2010 1998 ­ 2000 2008 1987 ­ 1993
CT completed 72/79 (91.1%) ­ ­ 68.6%
CT completed and 
results published 
35/72 (48.6%) 43.0% 70.5% 30.3%
CT published with 
positive outcome
29/35 (82.9%) ­ ­ 73.6%
CT published within 
2 years
27/72 (37.5%) ­ ­ ­
CT published within 
3 years
­ 92.0% ­ ­
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On a positive note, the South African Medical Research Council has 
signed the AllTrials petition.[21] However, other medical organisations 
in SA have yet to do so. As a result of AllTrials and similar campaigns, 
the European Union Parliament passed a regulation (effective May 
2016) that requires all clinical trials conducted in Europe to be 
registered before commencement of the clinical trials, and the results 
of the trials to be reported within a year of completion.[22] 
On 29 July 2015, the AllTrials campaign was officially launched in 
the USA. The USA now joins a worldwide campaign ‘calling for every 
clinical trial – past, present, and future – to be registered and the 
results from it reported’.[23] Furthermore, investors from Europe and 
the USA who are in support of the AllTrials campaign and who hold 
a combined USD35 trillion investment in pharmaceutical companies 
have added to the advocacy by requesting these companies to disclose 
trial results.[23]
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